Welcome to our dedicated page for Livanova news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on Livanova stock.
LivaNova PLC reports developments as a global medical technology company focused on selected neurological and cardiac conditions. Company news commonly covers revenue results and guidance, performance in its Cardiopulmonary and Epilepsy businesses, and updates tied to medical-device commercialization and clinical evidence.
Recurring product themes include VNS Therapy for drug-resistant epilepsy, real-world evidence from the CORE-VNS study, and obstructive sleep apnea technology using proximal hypoglossal nerve stimulation. Updates also include FDA regulatory decisions, including premarket approval for the aura6000 System, investor conference appearances, and business update calls.
LivaNova PLC (Nasdaq: LIVN) reported strong first-quarter 2024 results with revenue of $294.9 million, a 12.0% increase, and adjusted diluted earnings per share of $0.73. The company raised its full-year 2024 revenue guidance to grow between 6-7% on a constant-currency basis. LivaNova achieved positive trial outcomes in the OSPREY clinical study for obstructive sleep apnea. The company closed a private offering of $345.0 million convertible senior notes due 2029 and repurchased $230.0 million exchangeable senior notes due 2025.
LivaNova PLC announced the appointment of Ahmet Tezel, Ph.D., as Chief Innovation Officer, effective May 13, 2024. Tezel will lead the development of new technologies leveraging his 20+ years of experience in research and development. His role will enhance the Company's innovation capabilities in neurological and cardiac health.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.